If current inhibition and mortality reduction in heart failure : more than just a 'pure' effect of lowering heart rate by unknown
www.kardiologiapolska.pl
Kardiologia Polska 2013; 71, 7: 764–767; DOI: 10.5603/KP.2013.0168 ISSN 0022–9032
ARTYKUŁ POGLĄDOWY / REVIEW ARTICLE
If current inhibition and mortality reduction  
in heart failure: more than just a ‘pure’  
effect of lowering heart rate
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więcej niż „czysty” efekt obniżenia częstości rytmu serca
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IF IN THE HEALTHY HEART: SINOATRIAL  
NODE-LIMITED F-CHANNEL EXPRESSION AND 
‘PURE’ HEART RATE REGULATION
Cardiac pacemaking is a basic process in health and disease. 
The If current (often called ‘funny’ due to its many unusual 
properties) is an inward mixed Na+ and K+ current which 
is activated at negative cell membrane potentials (hence 
hyperpolarisation-activated) but whose activation causes 
spontaneous diastolic depolarisation [1]. These If properties 
are suited to the generation of repetitive electrical activity and 
the modulation of spontaneous rate [1]. Indeed, the degree 
of activation of the funny current determines the steepness 
of spontaneous depolarisation and thus the frequency of 
spontaneous firing in sino-atrial node (SAN) cells [1]. Because 
If is controlled by intracellular cAMP and thus is regulated by 
beta-adrenergic and muscarinic receptor agonists, it mediates 
the autonomic regulation of heart rate (HR) [1]. Furthermore, 
independent of autonomic modulation [2, 3], If is regulated 
by nitric oxide (NO) [4] through an intracellular pathway that 
involves cGMP and mobilisation of intracellular calcium [5]. 
The inhibition of endogenous NO production is associated 
with a reduction in HR both in vitro [6] and in vivo [2, 7], 
indicating that endogenous NO exerts a tonic positive chrono-
tropic effect [2, 6]. Because of the many unusual features of If, 
it had been queried whether such a large body of properties 
could correspond to one single current. This was until the 
If molecular basis became clear with cloning the f-channels 
[8], which confirmed a unique structural basis for this specific 
membrane current [9]. Under normal physiological conditions, 
If is functionally expressed exclusively in the SAN cells [1].
Thus the principal publication from SHIfT (Systolic Heart 
Failure Treatment with the If Inhibitor Ivabradine Trial) in 
Lancet in 2010 rightly states that: “[beyond If inhibition in 
SAN] in healthy hearts (…) ivabradine has no action on other 
channels in the heart or vascular system” [9].
HUMAN HEART FAILURE: IF IS FUNCTIONALLY 
EXPRESSED IN VENTRICULAR MYOCYTES
If is functionally inactive in normal (undiseased) ventricles, 
both because of very low expression of f-channels in the 
cardiomyocyte membrane and because of too negative, 
unphysiological voltage range of If activation [1, 10]. Marked 
upregulation of If expression in the ventricular myocardium, 
however, has been reproducibly documented in several 
animal models of heart failure (HF) and in humans suffering 
from HF in systematic studies of left ventricular (LV) myocytes 
sampled during cardiac surgery in HF patients [1, 10–12]. 
Moreover, in myopathic ventricular cells, in the presence of 
catecholamines, the If activation threshold is shifted towards 
less negative potentials and thus the current becomes func-
tional at normal diastolic potentials [11, 13]. In ventricular 
myocytes, an If-dependent diastolic depolarisation may lead 
to generation of a propagated action potential — similar to 
the role played by If in SAN [13]. By favouring spontane-
ous diastolic depolarisation in myopathic cells, If-generated 
ectopic ‘pacemaker-like’ action potentials in the ventricular 
myocardium provide a mechanism of ventricular arrhythmia 
[10, 11] and arrhythmic death in HF [12, 13].
Thus, in HF the If channel is up-regulated in human 
ventricular myocardium through its amplified expression [14]. 
Moreover, in human HF this current also becomes functional 
at normal potential range and may generate spontaneous 
diastolic depolarisation in diseased ventricular myocytes, 
similar to its physiological role in the SAN cells [11–15]. 
If overexpression and its altered regulation in failing cardiac 
myocytes (causing, as documented in humans, functional 
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availability of this current in the ventricular myocardium) 
represents an arrhythmogenic mechanism in HF [1, 11–15].
HEART FAILURE IS ASSOCIATED WITH  
AN INCREASE IN IF STIMULANTS
Not only is If functionally expressed in failing LV myocytes 
[11–15] but also HF is associated with an increase in known 
If stimulants. Activation of the adrenergic nervous system [16] 
and increased myocardial NO production [17] are the hall-
marks of HF. LV gene expression of constitutive NO synthase 
increases with the extent of LV dysfunction and the protein 
level of both (i.e. constitutive and inducible) NO synthases 
is increased in the failing myocardium [17]. Elevated expres-
sion of cardiac inducible NO synthase, as seen in patients 
with severe HF, attenuates responsiveness to beta-adrenergic 
stimulation [18], and there is ongoing research into the com-
plexities of NO-dependent molecular mechanisms in HF [19]. 
To some surprise, in ventricular myocytes in a spontaneously 
hypertensive rat model, NO donors or NO synthase inhibition 
did not alter the amplitude or voltage dependence of If activation 
[20]. Nevertheless, the rat (in contrast to some other mammalian 
species) is not an optimal model of human cardiac disease [21] 
due to several important differences in cardiac myocyte electro-
physiology [21–23]. Therefore continued study of human [21, 
24] myocardial cells, as in the case of If expression and activation 
characteristics [10, 11, 14, 15], is of paramount importance in 
clinical reference to human cardiac pathophysiology [21].
The increased adrenergic tone in HF is associated, at the 
SAN level, with HR elevation [25] whereas at the level of the 
ventricular myocardium, cathecholamines are an established 
trigger of ventricular arrhythmia [16, 26]. Indeed, sympathetic 
activation in HF has a profound arrhythmogenic impact [27], 
and evidence indicates that part of this impact may occur 
via ventricular myopathic cardiocyte If stimulation [11–15].
IF-DEPENDENT PATHOLOGICAL  
ELECTRIC ACTIVITY IN VENTRICULAR  
MYOCYTES IS ABOLISHED BY IF BLOCKADE 
Patch-clamping experiments in failing human ventricular 
myocytes have revealed that the If current characteristics 
are consistent with feasibility of its activation in the failing 
ventricular myocardium and that this effect, as expected, is 
further promoted by If stimulants [11–15]. The If current block-
ers (including ivabradine) inhibit the ventricular If channels 
similar to their mode of action in SAN cells [1].
Ventricular If contribution to the increased risk of ma-
lignant ventricular arrhythmias and sudden death in patients 
with HF, through favouring spontaneous diastolic depolarisa-
tion in ventricular myocytes [1, 12, 13], has been recently 
mimicked by experimental, forced ectopic expression of If in 
a normal myocardium using somatic gene transfer (recombi-
nant adenovirus gene carrier) of the ‘pacemaker’ f-channels 
[28]. Such forced If overexpression in undiseased ventricular 
myocytes leads to abnormal ventricular automaticity (via 
spontaneous gradual phase 4 depolarisation that is normally 
typical of SAN cells) [28]. This abnormal electric activity is 
enhanced by adrenergic stimulation [28, 29] and is sensitive 
to pharmacologic inhibition with ivabradine, consistent with 
a direct, causal role of If [28]. Indeed, If blockers, including 
ivabradine, have been demonstrated to inhibit ventricular ar-
rhythmias that occur when normal ventricular myocardium is 
overexpressed with f-channels [28, 29], mimicking the effect 
seen with enhanced If expression and its facilitated activation 
in the ventricular myocardium in HF.
SHIFT DEMONSTRATES REDUCTION OF HEART  
FAILURE-RELATED MORTALITY WITH IF INHIBITION
In the recent SHIfT study [9], 6,505 patients with chronic HF 
were randomised to treatment with the If inhibitor ivabradine 
or a placebo on top of what was considered standard medical 
therapy. This study demonstrated that, over a median period of 
22.9 months, ivabradine treatment was associated with a sig-
nificant reduction of the combined endpoint of cardiovascular 
death or hospital admission for worsening HF (24% vs. 29%, 
p < 0.0001, primary endpoint of the study) [9]. If inhibition 
with ivabradine was also associated with a significant reduc-
tion of death from HF (3% vs. 5%, p = 0.014, pre-specified 
secondary endpoint) [9], bringing new focus to the clinical 
relevance of If modulation in disease states. 
Because of the role in normal cardiac electrophysio-
logy, If (and If inhibition) have been commonly associated 
exclusively with the SAN [9, 30–34]. Thus, analyses of the 
cardiovascular outcomes in SHIfT have been focused on the 
magnitude of HR reduction and suggested (unsurprisingly) that 
the treatment effect of ivabradine was accounted for by HR 
reduction [30–33]. As recently found, the therapeutic effect 
of If blockade in HF was particularly pronounced in patients 
with baseline HR ≥ 75 bpm (cutoff indicated by the European 
Medicines Agency) [33] as in this patient group ivabradine 
reduced also all-cause mortality (hazard ratio 0.83, 95% CI 
0.72–0.96, p = 0.011) and cardiovascular mortality (hazard 
ratio 0.83, 95% CI 0.71–0.97, p = 0.012) [33].
Important beneficial mechanisms related to HR reduction 
in HF patients (and also in those with coronary artery disease) 
and the wider implications of SHIfT have been discussed in 
detail elsewhere [31–35].
LOWERING HEART RATE: A NON–EXCLUSIVE 
MECHANISM OF MORTALITY REDUCTION  
WITH IF INHIBITION IN HEART FAILURE
Could part of the mortality reduction benefit seen in HF 
with ivabradine treatment in SHIfT result from inhibition of 
the ‘pacemaker’ current If that is known to be functionally 
expressed [11–15] in the myopathic ventricular myocytes?
Arrhythmic death, unfortunately, was not a pre-specified 
endpoint in SHIfT [9] and, as it was not evaluated, SHIfT re-
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ports do not include any specific data on arrhythmic death [9]. 
Therefore there is no level 1 evidence for a clinically-relevant 
role of ivabradine occurring through inhibition of the abnormal 
If-dependent spontaneous electric activity in the ventricular 
myocytes. While it would be theoretically possible (though, 
given the current guidelines [34, 35], ethically difficult) to de-
sign a placebo-controlled arrhythmic death-focused study with 
If blockade in HF, execution of such a study is highly unlikely 
also because reliable documentation of arrhythmic death as 
the study endpoint would require continuous, telemetric ECG 
monitoring in all study subjects (with the population size and 
follow-up period exceeding that of SHIfT).
Malignant ventricular arrhythmia such as ventricular 
tachycardia (VT) or ventricular fibrillation is one of the prin-
cipal mechanisms of death in HF [36, 37]. The presence of 
non-sustained VT on 24 h continuous ECG recording increases 
the odds of dying about three-fold over a 1–2 year follow-up 
period [36], and ventricular arrhythmia is a documented trigger 
event in the development of fatal arrhythmia [38]. Unfortunately, 
history of VT (unless a cardioverter-defibrillator, ICD, was already 
implanted) or, in those with ICD-ICD shock within six months 
prior to randomisation, were exclusion criteria from participation 
in SHIfT [9], minimising a priori the potential of SHIfT to detect 
the benefit of malignant ventricular arrhythmia suppression 
occurring through ‘ventricular’ If inhibition with ivabradine. 
Despite this important limitation, SHIfT still demonstrated 
a mortality benefit [9, 33], part of which is likely to arise from 
the action of ivabradine in diseased ventricular myocardium. 
Heart failure death was a pre-specified endpoint in SHIfT, 
and it is well-known that lethal arrhythmias do occur in asso-
ciation with HF worsening [36, 37]. There is evidence that in 
HF exacerbation [9], a significant proportion of ‘pump failure’ 
deaths do overlap with arrhythmic deaths [36]; thus it is often 
impossible to clearly distinguish one mode of death from the 
other [36]. One should also take into account that the failing 
heart undergoes complex electrical remodelling of ventricu-
lar myocytes [39], and functional If expression in ventricular 
myocytes [10, 11, 14, 15] is one of several mechanisms that 
promote ventricular arrhythmia. Mapping experiments have 
demonstrated that ventricular arrhythmias in HF are mainly 
due to non-reentrant mechanisms [38]; an effect consistent 
with a role of If-dependent abnormal automaticity [12, 13, 15].
Suppression of If-dependent spontaneous abnormal electri-
cal activity in the diseased LV achieved via If inhibition — leading 
to the mortality reduction with ivabradine in HF — is an allur-
ing hypothesis that is supported by several lines of patho- and 
electrophysiological evidence. These lines of evidence include 
(i) documented functional expression of If in ventricular myo-
cytes in human HF [10, 11, 14, 15], (ii) an HF-associated increase 
in If stimulants such as the adrenergic drive and myocardial NO 
production [16–19, 26–27], and (iii) documented ivabradine 
suppression of abnormal electrical activity associated with 
If overexpression in the ventricular myocardium [28, 29].
Although analysis of the cardiovascular outcomes in 
SHIfT [9] has suggested that the treatment effect of ivabradine 
in HF is accounted for by HR reduction [9, 29], the degree of 
HR reduction with ivabradine is likely to reflect the degree 
of If inhibition not only in the SAN but also the degree of 
f-channel inhibition in the ventricular myocardium. Thus the 
widely documented association of the magnitude of clinical 
benefit of If inhibition with the degree of HR reduction in 
HF [30–33, 35] is not in any conflict with the contributory 
effect of If inhibition in ventricular myocytes that leads to 
malignant automaticity suppression (i.e. the more effective, 
or the better response to,  If inhibition in terms of heart rate 
reduction magnitude, the more effective is the inhibition of 
the pathologically expressed If in the myopathic ventricular 
cells). 
In HF, increased HR is a marker of increased sympathetic 
activation [25, 40, 41], and increased sympathetic activation 
stimulates malignant ventricular arrhythmias [16, 26] while 
the functional expression of If in the myopathic ventricular 
myocytes provides an important arrhythmic mechanism 
[11–15] that is sensitive to adrenergic stimulation [12–15]. The 
relative contribution of the two mechanisms (i.e. HR reduc-
tion as a result of ivabradine action in the SAN and malignant 
arrhythmia suppression as a result of ivabradine action in the 
ventricular myocardium) to the observed mortality reduction 
[9, 33] is impossible to dissociate because pharmacologic 
If blockers inhibit If both in the SAN and likewise in the fail-
ing ventricular myocytes [1, 10, 11, 14, 15, 29]. Thus the HR 
reduction seen with ivabradine in HF may be, to an extent, 
an epiphenomenon of the ‘ventricular’ If inhibition that (also) 
occurs with ivabradine treatment. For this reason, it is not sur-
prising that (i) in SHIfT patients with baseline HR ≥ 75 bpm (an 
index of increased sympathetic drive) [25, 40, 41], ivabradine 
significantly reduced not only HF-related death (hazard ratio 
0.61, 95% CI 0.46–0.81, p < 0.001) but also all-cause mor-
tality (hazard ratio 0.83, 95% CI 0.72–0.96, p = 0.011) and 
cardiovascular mortality (hazard ratio 0.83, 95% CI 0.71–0.97, 
p = 0.012) [33], and (ii) that the primary determinant of study 
outcomes was, as shown recently, the magnitude of HR reduc-
tion by ivabradine combined with beta-blocker, and not the 
background beta-blocker dose [42].
When taken together, the evidence indicates clearly that 
part of the therapeutic effect of ivabradine in HF may be as-
sociated with the inhibition of the ‘pacemaker’ current If in 
the diseased ventricular myocytes. Interestingly, a functional 
role of the pathological If expression in ventricular myocytes 
has been proposed [2, 4, 43] following the discovery of 
a novel If-dependent signalling pathway in the SAN cells [2–4]. 
Fifteen years later, an overlooked [9] mechanism [1, 11–15] 
would undoubtedly benefit from its further elucidation in the 
context of novel data [9, 34] that is consistent with a clinical 
relevance of If that extends beyond heart beat generation 
and HR regulation.
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CONCLUSIONS
While the popular assumption that the action of If inhibitors 
is limited to the sino-atrial node [9, 34] is true for the healthy 
heart [1], several lines of evidence indicate that this assump-
tion may not hold for the failing human heart [11, 15, 28, 29]. 
By favouring spontaneous diastolic depolarisation in ventricu-
lar myocytes, the If current (which is functionally absent in 
normal ventricular myocardium but is functionally expressed 
in human failing cardiomyocytes [11–15]), may contribute to 
the increased risk of malignant ventricular arrhythmias and 
death in patients with HF; an effect responsive to If blockade 
[28, 29]. Several lines of evidence indicate that part of the 
mortality reduction seen with ivabradine treatment in SHIfT 
[9, 33] may result from inhibition of the ‘pacemaker’ current 
If in the diseased ventricular myocytes. Thus, when it comes 
to mechanisms behind the recently demonstrated mortality 
reduction [9, 33] in HF patients treated with an If inhibitor, 
there is likely to be more than just a ‘pure’ heart rate–lowering 
effect of the If blockade!
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